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Introduction: Complete androgen insensitivity (CAIS) in 65–95% cases is caused by
pathogenic allelic variants (mutations) in the gene encoding androgen receptor (AR gene)
and is characterized by female phenotype development with a male karyotype (46,
XY). Patients are usually diagnosed during puberty and undergo gonadectomy due to
increased testicular germ cell tumor risk. Only a few outcomes have been reported in
older individuals with postponed gonadectomy.
Case presentation: A 48-year-old CAIS patient presented with polyorchidism (four
testes) without gonadal malignancies. Genetic testing identified a novel allelic variant in
the AR gene [c.2141T>G (p.Phe805Cys)] causing the clinical symptoms.
Conclusion: We have described a unique patient with CAIS and polyorchidism without
malignancies in her late 40’s bearing a novel likely pathogenic variant in the AR gene.
Keywords: complete androgen insensitive syndrome, androgen receptor (AR) gene, polyorchidism, supernumerary
testis, novel genetic variants, case
INTRODUCTION
Complete androgen insensitivity syndrome (CAIS) is a congenital disorder ofi sex development
that is characterized by a female phenotype and a 46, XY karyotype due to allelic variants
in the androgen receptor (AR) gene (NCBI Gene ID: 367, OMIM#313700), which is located
in the X-chromosome (1, 2). These changes lead to complete resistance to the biological
actions of androgens and fetal sex differentiation into a female phenotype. In adolescence,
CAIS is characterized by excess aromatization of androgens to oestrogens and the absence of
opposing androgen action due to androgen receptor dysfunction with consequent development
of secondary female characteristics (2, 3). For a long time, generally accepted recommendations
suggested performing gonadectomy after puberty due to the risk of malignancy (4). However,
recent studies have revealed a slightly lower risk of developing testicular germ cell tumors of
approximately 5% in androgen insensitivity syndrome (5), and although germ cell neoplasia in
situ is found in 14% of patients, malignant progression appears to be a rare (6). Therefore, the
practice of routine prophylactic gonadectomy in adults with CAIS appears questionable and the
recommendations—less stringent (7).
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CASE SUMMARY
Clinical Description
This study was carried out in accordance with the
recommendations of “Central Ethical Committee of Latvia”
with written informed consent from all subjects. All subjects gave
written informed consent in accordance with the Declaration
of Helsinki. For control samples there were only genotyping
performed, for patient sample were obtained written informed
consent for study and publication, clinical data, and anamnesis
were collected retrospectively.
A 48-year-old patient was admitted to the hospital in August
2016 with a suspected testicular germ cell tumor due to CAIS. The
patient’s main complaints included progressive and transitory
edema, general malaise and a mobile formation in the left
groin gradually grown to 2.5 cm over the previous 4–5 months.
General examination showed a female phenotype (Prader stage
0, Tanner grade V breast development), generalized edema (stage
I/II), Body Mass Index (BMI) 32 kg/m2 and an elevated blood
pressure of 180/120 mmHg. During physical examination, a
freely moveable, non-painful oval mass was noted in the left
inguinal canal. A similar smaller mass was also found in the
right inguinal canal. External genital organs were normal on
examination. A hypoplastic, yet functional, vagina with a vaginal
canal length of 4.5 cmwas present. The patient was sexually active
and exhibited sexual well-ness.
CAIS had been detected in 1986, when the patient was
examined due to primary amenorrhea, and her karyotype was
analyzed and confirmed 46, XY karyotype. At the age of 26, the
patient underwent right side hernia repair surgery during which
the descended testis was mistakenly reduced to the abdominal
cavity without gonadectomy.
The patient had a medical history of particular interest, which
included bilateral middle cerebral artery aneurysm embolization
with microspirals. After procedure there were followed without
discontinuation of treatment with 5mg of Perindopril and BP
was 125/80 mmHg on this treatment.
At the time of admission to the hospital, a biochemical
evaluation revealed expected luteinizing hormone (LH), follicle-
stimulating hormone (FSH), testosterone, and androstenedione
levels. The dynamics of all the hormonal levels are shown in
Table 1.
Testing was performed for germ cell malignancy markers
and showed normal levels: beta-human chorionic gonadotropin
< 1.20 mIU/mL (reference range < 5 mIU/mL), and alpha-
fetoprotein 1.78 ng/mL (normal range < 6.7 IU/mL).
Further outpatient investigations including a pelvic
ultrasound and magnetic resonance imaging (MRI) examination
revealed oval structures in both inguinal canals; the testicular
parenchyma was markedly heterogeneous with nodular
structures. We performed another pelvic MRI examination,
which identified a residual testicular structure measuring 9.5 cm3
in the right hypogastrium. On diffusion weighted imaging (B =
600), the formation had high signal intensity and the apparent
diffusion coefficient was >1; no paratesticular cysts were found.
The lesions were characterized as benign; however, imaging
could not rule out a premalignant transformation (Figure 1).
The patient underwent a two-stage surgical intervention
with the first stage of bilateral orchidectomy performed through
an inguinal approach in September 2016. After visualization
with haematoxylin-eosin stain, the testicular morphology
showed extensive atrophic changes in the seminiferous tubules
in association with Leidig cell hyperplasia (Figure 2). The
morphology was remarkably heterogeneous in regard to
the degree of atrophy and extent of Leidig cell hyperplasia.
Seminiferous tubules featured extensive thickening of
basement membranes along with hyalinisation of collagen.
Consequently, the epithelium of most tubules had totally
or almost completely disappeared, and these tubules were
converted into homogeneous eosinophilic nodules. In the
remaining tubules, Sertoli cells were found. The tubular lumina
were either small or entirely lost. No signs of spermatogenesis
were evident in multiple sections. Leydig cells were abundant
although they lacked Reinke’s crystalloids.
To exclude germ cell neoplasia in situ, the following
intratubular cellular features were sought for: crowding and/or
overlapping of nuclei, manifestations of cellular atypia such
as increased cell diameter or presence of giant cells; enlarged,
angulated, hyper- or hypochromatic nuclei; coarse structure of
chromatin; nuclear pleomorphism; increased nucleo-cytoplasmic
ratio; enlarged nucleoli; presence of mitoses, or atypical mitoses
and/or foci of necrosis and dystrophic calcifications (microliths).
Acknowledging the characteristically patchy nature of germ cell
neoplasia in situ, multiple sections (3 per cm of diameter) were
evaluated in haematoxylin-eosin stain. The intratubular cells did
not show any of the listed traits of germ cell neoplasia in situ.
Atrophic rete testis was identified lacking any signs of cellular
proliferation. The blood vessels were mostly intact but focal
hyalinisation was evident in small arteries and arterioles.
Notably, one of the two obtained specimens consisted of two
coalesced testes.
During the second stage of the surgical procedure, a
laparoscopic orchidectomy was performed. The following
histopathological examination yielded morphological findings
that were identical with the previously described. After the
second surgery, the patient’s clinical presentation improved
significantly; the postoperative laboratory results (hormonal
analyzes taken in next day after the surgery) are shown inTable 1.
In addition, 1 month after surgery, she had successfully reduced
her weight to a BMI of 29.3 kg/m2 and had a stable blood pressure
125/80 mmHg.
Further recommendations included hormone replacement
therapy with estradiol as a transdermal spray (Lenzetto R©
1.53mg), vaginal cream also containing estradiol (Linoladiol R©
0.01%), and antihypertensive therapy.
Genetic Analysis
To confirm the diagnosis genetically, PCR and bidirectional
Sanger sequencing for the coding regions and exon/intron
boundaries of the AR gene (NCBI Gene ID: 367, OMIM#
313700) were performed using a BigDye Terminator
kit v.3.1. (Applied Biosystems, USA), according to
the manufacturer’s protocol. Previously described
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TABLE 1 | Preoperative and postoperative laboratory blood tests in the patient.




After the first surgery
(September 2016)
After the second surgery
(December 2016)*
LH, IU/L 1.4–7.7 13.2 16.0 24.6
FSH, IU/L 1.5–14 15.4 22.9 40.6
Estradiol, pg/ml <56 48.4 46.6 21.5
Testosterone, ng/ml 3.3–8.05 18.27 5.28 0.14
Androstenedione, ng/ml 0.3–3.3 3.79 2.63 3.42
FIGURE 1 | Preoperative MRI revealed oval structures without follicular activity: (A) right side (showed with an arrow) −1 × 1.3 cm, located near the anterior
abdominal wall; (B) left side (showed with an arrow) −2.6 × 1.6 cm, located in the left inguinal canal; (C) pelvic MRI fat-suppressed T2 sequence of the right
hypogastrium with a residual testicular structure 1.2 × 2.4 × 3.3 cm (showed with an arrow).
primers (8) were used, and the obtained sequence was
analyzed and compared with the reference sequence
NG_009014.2.
Previously unreported genetic variation with amino acid
changes in the ligand binding domain (LBD) of the 6th exon
of the AR gene, where phenylalanine at the 805th position was
exchanged for cysteine (according to Human Genome Variation
Society nomenclature: NC_000023.11:g.67721928T>G,
NG_009014.2:g.182897T>G, NM_000044.3:c.2414T>G,
NP_000035.2:p.Phe805Cys) was found (Figure 3). Guidelines
for variation interpretation by the American College of Medical
Genetics (ACMG) (9) were used to analyse the pathogenicity of
the novel variation.
To analyse the frequency of the novel allelic variant,
sequencing of 100 X chromosomes (25 women and 50
men) of the 6th exon of the AR gene was performed in
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FIGURE 2 | Morphologic findings in surgically removed testes. (A) Marked tubular atrophy. Note the thickening and hyalinisation of the basement membrane as well
as complete loss of tubular cells (arrows). Haematoxylin-eosin (HE), original magnification (OM) 200x. (B) Absence of spermatogenesis (arrow). Note also the nuclear
features justifying the absence of germ cell neoplasia in situ. HE, OM 400x. (C) Extensive hyperplasia of Leydig cells (arrow) adjacent to atrophic tubules. HE, OM
200x. (D) Morphology of Leydig cells (arrow). Note the absence of Reinke’s crystalloids. HE, OM 400x. (E) Rete testis. HE, OM 200x. (F) Hyalinisation in an arteriole
(arrow). HE, OM 200x.
healthy individuals from the general population of Latvia:
none of them had the same variation, confirming that
the detected variant was rare. There were no reported
variations in this nucleotide according to the ClinVar
database (10) at the time of preparation of this manuscript
(06.07.2018.); however, two other variants in the same
codon, where phenylalanine was exchanged for isoleucine
and leucine (p.Phe805Leu and p.Phe805Ile) (11, 12) were
reported in the Leiden Open Variation Database (LOVD)
(13).
To computationally detect the pathogenicity of the identified
variant, multiple in silico prediction tools as SIFT, PolyPhen,
Condel, Mutation Taster were used (14–16), and it was classified
as a deleterious variant (Pathogenity score in SIFT= 0; PolyPhen
= 0.0997; Condel = 0.619; Mutation taster result—disease
causing).
According to the ACMG variation interpretation guidelines,
the discovered mutation was classified as likely pathogenic (PM2,
PM5, PP3, PP4 criteria) confirming that CAIS could be diagnosed
molecularly (9). Variant segregation in the patient’ s family could
not be performed because the patient did not have any relatives
(the patient’s parents were deceased, and the patient did not have
any siblings).
DISCUSSION
This case report describes the characteristic findings of CAIS,
such as primary amenorrhea, inguinal hernia (observed in
adolescence), karyotype 46, XY and female phenotype. It
is unique in the way notable distinctions were revealed in
the form of long-term complications of retained testicular
structures without malignancy despite improper repositioning,
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and in the rare form of polyorchidism or supernumerary testis
(tetraorchidims) and novel genetic variant causing CAIS.
Polyorchidism is a very rare congenital anomaly. Only around
200 cases have been described in the literature until 2017: (17)
and only several cases in last years reported tetraorchidism
(18–21). To our knowledge, this is the first reported case of
CAIS with polyorchidism although not the first in persons
with disorders of sexual differentiations. The mechanism of
polyorchidims is unknown, some researchers suggest it is
caused of incomplete degeneration of the mesonephros or
aberrant division or duplication of the genital ridge before
8 weeks gestation account for testicular duplications (21).
Besides there are reports describing polyorhidism associated
with chromosomal syndromes (17), and in number of cases
in disorders of sexual differentiation (in karyotype 46,XX (22),
46,XY DSD (23), we believe that it is independent findings.
In patients with CAIS, it is recommended that gonadectomy
be performed after puberty so that the occurrence of spontaneous
puberty is not affected and because prepubertal malignancies
are rarely reported (24). One of the largest studies performed
involved the Cambridge Disorders of Sexual Development
Database and evaluated 113 patients with CAIS, focusing on
gonad malignancies. This study showed that the malignancy rate
was 1.5%; however, only 13 patients underwent gonadectomy
after 20 years of age; the others underwent surgery at
an earlier age (25), so it was hard to evaluate long-term
malignancies. However, in another study, it was reported
that malignancies occur in up to 3.5% of all patients with
CAIS who do not undergo gonadectomy by 25 years of age
and in 33% of those who do not undergo gonadectomy
by 50 years of age; it is also known that in patients
with CAIS, malignancies are found more rarely than in
patients with partial androgen insensitivity, confirming that
the development of malignancy depends on residual androgen
activity (26). The case described in this publication confirms
that gonadectomy in patients with CAIS should be considered
individually. Even though the malignancy rate is low at
an earlier age, gonads can still affect the patient’s clinical
status later even without malignancy. The optimal follow-
up strategy is also unclear because characteristic germ cell
tumor markers, such as α-fetoprotein and β-HCG, are rarely
elevated in association with seminomas and are never elevated
in association with neoplasia in situ (27). Although targeted
ultrasound or MRI can demonstrate the same suggestive findings
even with early stage neoplasia, most often neoplasia remains
undiagnosed with imaging methods (28, 29). The most available
diagnostic technique is in theory is genetic variations (single
nucleotide polymorphism) based malignancy risk susceptibility
profiling (6). In our patient there were not observed any
malignancy despite the fact that gonadectomy performed at age
of 40ies.
The diagnosis of CAIS in the described patient was also
confirmed with DNA analysis. A novel allelic variation was
identified in the 6th exon of the AR gene that according
to the ACMG interpretation guidelines (9) was classified as
likely pathogenic thus confirming the disease. The frequency
of detection of pathogenic variations in the AR gene in
patients with CAIS ranges from 65 to 95% (30), although
percentage could be even higher because in latest reports are
described variants also in non-coding parts of the gene (31).
The androgen receptor consists of three functional domains:
an N-terminal transcription-regulation domain (encoded by the
1st exon), a DNA-binding domain (encoded by the 2nd and
3rd exons) and a C-terminal ligand-binding domain (LBD)
(encoded by the 4–8th exons). In 56.5% of all patients with CAIS,
including the patient described in this paper, allelic variation
are located in LBD, thus this locations has the highest identified
pathogenic variations density (32). Allelic variations in the
LBD affect binding affinity or retention of dihydrotestosterone
and testosterone to androgen receptors, thus leading to CAIS.
Some AR LBD allelic variations do not affect ligand binding,
but they disrupt androgen-induced N-terminal and C-terminal
FIGURE 3 | Electropherogram of the novel variation in the 6th exon of the AR gene (HGVS nomenclature: NC_000023.11:g.67721928T>G,
NG_009014.2:g.182897T>G, NM_000044.3:c.2414T>G, NP_000035.2:p.Phe805Cys).
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domain interaction, which also causes diminished androgen
activity and results in a changed phenotype (CAIS) (1). We think
that identified variant is causing CAIS but we don’t have any
evidence supporting hypothesis that it could be associated with
polyorchidism.
The patient had a medical history included bilateral middle
cerebral artery aneurysm that most likely is independent finding,
however one similar case is described previously (33). Speculative
correlation could be based on fact that patient had hypertension,
that is known risk factor for cerebral aneurysm (34). However,
male gender is protective as defective androgen receptor is
defect abolishes sex differences in nitric oxide and reactivity
to vasopressin so leading to more female gender specific
effects (35).
Unfortunately, information regarding the patient’s family
was not available, so we could not determine whether the
novel variant occurred de novo or was inherited; however in
the first large cohort study by Morris (82 patients observed
during the period from 1817 to 1953), it was reported
that there was a strong familial connection, as shown by
the number of sisters with the same findings (36); other
studies also showed a high prevalence of inherited cases and
mentioned de novo disease in only 30% of the patients (37).
Patient infertility prevents direct inheritance from affected
individuals.
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